Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2고혈압은 비활성화된 SARS-CoV-2 백신 접종 후 의료 종사자의 항체 반응 및 돌발성 감염과 관련이 있습니다.Article Published on 2022-06-262022-09-12 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Affect age analysed antibody Antibody Response Antibody titre antibody titres association blood pressure blood sample BMI body mass index Breakthrough infection clinical parameter clinical variable collected Comorbidity CoronaVac coronavirus disease correlated COVID-19 COVID-19 vaccination demographic characteristics demographic data dose Effectiveness Efficacy enrolled exhibited Factors Health care worker healthcare worker hypertension IMPROVE inactivated Inactivated viral vaccine. incidence medical history Prevent questionnaire Retrospective study SARS-CoV-2 second dose Sex significantly vaccination Vaccine Vaccines virus [DOI] 10.1016/j.vaccine.2022.05.059 PMC 바로가기 [Article Type] Article
COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection혈액 투석실에서 예방 접종을 받은 환자의 COVID-19 발생: 감염으로부터 보호하는 지표로서의 항체 역가Article Published on 2022-06-232022-09-11 Journal: Nephrology, dialysis, transplantation : official p [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] 95% CI acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha Alpha variant anti-S anti-S IgG Anti-spike Antibody titre BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccination BNT162b2 vaccine Casirivimab cause Clinical data Combination confidence interval coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 infection COVID-19 outbreak dialysis dialysis room Haemodialysis humoral Humoral response identify IgG Imdevimab immune correlate immune correlates Immunoglobulin Immunoglobulin G Immunosuppression increased risk Infection interquartile range IQR marker monoclonal antibodies monoclonal antibody mRNA vaccination multivariable analysis neutralization Odds ratio outbreak Patient patients prevented recorded reduced respiratory SARS-CoV-2 SARS-COV-2 infection serological response severe acute respiratory syndrome Coronavirus severe coronavirus disease severe COVID-19 severe disease the patient titre treated uninfected vaccination Vaccines variant were infected with COVID-19 [DOI] 10.1093/ndt/gfac016 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial6~17세 어린이 대상 ChAdOx1 nCoV-19(AZD1222) 백신의 안전성 및 면역원성: 2상 단일 맹검, 무작위, 대조 시험인 COV006의 예비 보고서Clinical Trial Published on 2022-06-112022-09-11 Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] 95% CI administration Adults adverse event adverse events age All participants anti-SARS-CoV-2 IgG antibody Antibody titre antibody titres arbitrary unit assigned AstraZeneca AZD1222 baseline capsular Cellular responses ChAdOx1 ChAdOx1 nCoV-19 children chronic respiratory conditions Concentration Controlled trial COVID-19 COVID-19 vaccine COVID-19 vaccines Cutoff Department dose doses Efficacy enrolled Fever first dose first vaccination four group four groups geometric geometric mean geometric mean ratios Geometric means group half-maximal inhibitory concentration Humoral response humoral responses immune response immune responses immunogenic immunogenicity in some intramuscular dose introduced investigators ISRCTN Laboratory laboratory-confirmed Laboratory-confirmed COVID-19 Local nucleocapsid protein Pain and tenderness participant Participants peaked Phase 2 phase 3 study preliminary report Primary outcome prime and boost raised randomised Randomly receive receiving recruitment Registered remained reported resolved respiratory response Safety safety population SARS-CoV-2 second dose second vaccination secondary outcome Serious Adverse Event Serious Adverse Events seronegative seronegative participant seronegative participants seropositive serostatus single-blind stratified study drug study groups tenderness Tolerability treatment allocation Trial vaccination Vaccine Viral viral particle were recorded [DOI] 10.1016/S0140-6736(22)00770-X PMC 바로가기 [Article Type] Clinical Trial
Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history백신 접종 및 감염 이력에 의한 SARS-CoV-2 Delta 및 Omicron 변이체에 대한 반응성 중화Article Published on 2022-06-102022-09-11 Journal: Genome Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료법, [키워드] Abbott anti-S antibody antibody antibody persistence Antibody Response Antibody titre antibody titres Antigen B.1 B.1.1.529 B.1.617.2 blood sample Blood samples Cohort collected control group control groups controls COVID-19 cross-protective Delta delta variant DiaSorin dose elicited followed by generate group healthcare healthcare worker Immune escape Immunity immunoassays increasingly individuals induce Infection investigated N antigen naïve naïve subject naïve subjects natural infection neutralisation neutralising Neutralising Antibodies nucleocapsid omicron Omicron variant performed persistence Post-infection presence of antibody question reactivity required Roche S antigen SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 strain SARS-CoV-2 variant SARS-CoV-2 variants sera Serosurvey serum significantly subject subjects tested the SARS-CoV-2 timepoints two groups vaccinated individuals vaccination Vaccine Vaccine development variant virus VoC VOCs weakened were used while [DOI] 10.1186/s13073-022-01066-2 PMC 바로가기 [Article Type] Article
Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials2개의 단일 센터 2상 임상 시험에서 CoronaVac의 추가 용량의 6개월 추적Clinical Trial Published on 2022-06-032022-09-12 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse event age Antibody titre booster booster dose clinical trial clinical trials contribute CoronaVac Determining dose double-blind Exploratory endpoints Follow-up follow-up period geometric mean titre GMT GMTs homologous humoral Immunity immunization immunization strategies increases in magnitude neutralising antibody neutralization Older placebo-controlled population immunity post-hoc analyses randomised recommendation recorded regimen Secondary endpoints titre [DOI] 10.1038/s41467-022-30864-w PMC 바로가기 [Article Type] Clinical Trial
Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies골수성 악성종양 환자에서 mRNA 기반 코로나19 백신에 대한 체액 반응Article Published on 2022-06-012022-09-12 Journal: British Journal of Haematology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute myeloid leukaemia AML Anti-spike Antibody titre appear comparable COVID-19 COVID-19 vaccine disease HCs healthy control humoral Humoral response Infection lymphoid malignancies malignancy MDs mRNA-based mRNA-based COVID-19 vaccine myelodysplastic syndrome. myeloid malignancies myeloid malignancy no significant difference Patient patients risk SARS-CoV-2 SARS-CoV-2 antibody titre SARS-CoV-2 vaccine significantly lower syndrome therapy Treatment vaccination Vaccine were measured [DOI] 10.1111/bjh.18138 PMC 바로가기 [Article Type] Article
SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World’s PopulationSM-COLSARSPROT: 전 세계 인구를 대상으로 하는 고 면역원성 초돌연변이 합성 펩타이드Article Published on 2022-05-252022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, [키워드] Amino acid Antibody titre Antigen presentation approach backbone complementary concerning Coverage Covering disrupting DNA E protein genetic variability Genetic variant genotyped histocompatibility complex human leukocyte antigen immune response induce Interaction leukocyte major histocompatibility complex methodology MHCII modified synthetic peptides molecular multiepitope mutant mutational variants Neutralising Antibodies neutralising antibody pandemic parental peptide peptides physicochemical polymorphism Population predicted replacing residues SARS-CoV-2 SARS-CoV-2 S selected Specific Structure supramutational synthesised synthetic synthetic peptides Trial Vaccine development vaccine for COVID-19 virus worldwide coverage. π-π interaction [DOI] 10.3389/fimmu.2022.859905 PMC 바로가기 [Article Type] Article
Factors associated with anti-SARS-CoV-2 antibody titres 3 months post-vaccination with the second dose of BNT162b2 vaccine: a longitudinal observational cohort study in western GreeceBNT162b2 백신 2차 접종 후 3개월째 항-SARS-CoV-2 항체 역가와 관련된 요인: 서부 그리스의 종단 관찰 코호트 연구Observational Study Published on 2022-05-192022-09-12 Journal: BMJ Open [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% CI age age and gender analyses anti-SARS-CoV-2 antibody Antibody Response Antibody titre antibody titres association baseline body mass index correlation COVID-19 COVID-19 pandemic COVID-19 vaccination criteria diabete diabetes Diseases eligible evaluate Factor Gender general endocrinology Greece healthcare highlighting Humoral immunity hypertension identify increasing age individuals Infectious diseases information Interaction investigated linear Linear regression analysis lower quartile male men Multiple obese Observational cohort study of BNT162b2 parameter Patra Patras positive receiving response to vaccination SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody titre SARS-CoV-2 antibody titres SARS-COV-2 infection second dose smoking state statistically significant subject tested titre Tobacco university vaccination Vaccine vitamin D level vitamin D levels was performed was used were excluded women [DOI] 10.1136/bmjopen-2021-057084 PMC 바로가기 [Article Type] Observational Study
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial
Improved immunologic response to COVID-19 vaccine with prolonged dosing interval in haemodialysis patients혈액투석 환자에서 투여 간격 연장으로 코로나19 백신에 대한 면역 반응 개선Article Published on 2022-05-012022-09-12 Journal: Scandinavian journal of immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] 2019 coronavirus disease affecting anti-SARS-CoV-2 anti-SARS-CoV-2 spike protein IgG antibodies antibody Antibody titre antibody titres BNT162b2 Combination coronavirus COVID-19 COVID-19 infection COVID-19 vaccine cross-sectional disease incidence dose doses dosing interval eligible Factor group Haemodialysis IgG IgG test immunologic response Improved Inclusion Increasing median mRNA vaccine mRNA-1273 not differ parameters Patient patients Phadia reduce respiratory syndrome coronavirus response rate SARS-CoV-2 SARS-CoV-2 antibody titre second dose serum calcium severity Spike protein Swedish Thermo Fisher Scientific titre vaccination vaccine dose Vaccines while [DOI] 10.1111/sji.13152 PMC 바로가기 [Article Type] Article